vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Gogo Inc. (GOGO). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $230.6M, roughly 1.1× Gogo Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -4.3%, a 15.5% gap on every dollar of revenue. On growth, Gogo Inc. posted the faster year-over-year revenue change (67.3% vs 29.6%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-25.4M). Over the past eight quarters, Gogo Inc.'s revenue compounded faster (48.7% CAGR vs 34.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Gogo Inc. is an American provider of in-flight broadband Internet service and other connectivity services for business aircraft, headquartered in Broomfield, Colorado. Through its Gogo LLC subsidiary, Gogo previously provided in-flight WiFi to 17 airlines until the Commercial Air business was sold to Intelsat for $400 million in December 2020. According to Gogo, over 2,500 commercial aircraft and 6,600 business aircraft have been equipped with its onboard Wi-Fi services. The company is the de...
ANIP vs GOGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $230.6M |
| Net Profit | $27.5M | $-10.0M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 6.2% |
| Net Margin | 11.1% | -4.3% |
| Revenue YoY | 29.6% | 67.3% |
| Net Profit YoY | 367.5% | 64.6% |
| EPS (diluted) | $1.14 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $230.6M | ||
| Q3 25 | $227.8M | $223.6M | ||
| Q2 25 | $211.4M | $226.0M | ||
| Q1 25 | $197.1M | $230.3M | ||
| Q4 24 | $190.6M | $137.8M | ||
| Q3 24 | $148.3M | $100.5M | ||
| Q2 24 | $138.0M | $102.1M | ||
| Q1 24 | $137.4M | $104.3M |
| Q4 25 | $27.5M | $-10.0M | ||
| Q3 25 | $26.6M | $-1.9M | ||
| Q2 25 | $8.5M | $12.8M | ||
| Q1 25 | $15.7M | $12.0M | ||
| Q4 24 | $-10.3M | $-28.2M | ||
| Q3 24 | $-24.2M | $10.6M | ||
| Q2 24 | $-2.3M | $839.0K | ||
| Q1 24 | $18.2M | $30.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 87.8% | ||
| Q1 25 | — | 87.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 14.1% | 6.2% | ||
| Q3 25 | 15.9% | 12.9% | ||
| Q2 25 | 6.6% | 15.9% | ||
| Q1 25 | 13.3% | 15.3% | ||
| Q4 24 | -2.3% | -17.5% | ||
| Q3 24 | -13.8% | 19.0% | ||
| Q2 24 | 3.7% | 21.2% | ||
| Q1 24 | 14.8% | 33.2% |
| Q4 25 | 11.1% | -4.3% | ||
| Q3 25 | 11.7% | -0.9% | ||
| Q2 25 | 4.0% | 5.7% | ||
| Q1 25 | 8.0% | 5.2% | ||
| Q4 24 | -5.4% | -20.5% | ||
| Q3 24 | -16.3% | 10.6% | ||
| Q2 24 | -1.7% | 0.8% | ||
| Q1 24 | 13.2% | 29.2% |
| Q4 25 | $1.14 | $-0.08 | ||
| Q3 25 | $1.13 | $-0.01 | ||
| Q2 25 | $0.36 | $0.09 | ||
| Q1 25 | $0.69 | $0.09 | ||
| Q4 24 | $-0.45 | $-0.22 | ||
| Q3 24 | $-1.27 | $0.08 | ||
| Q2 24 | $-0.14 | $0.01 | ||
| Q1 24 | $0.82 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $125.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $101.1M |
| Total Assets | $1.4B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $125.2M | ||
| Q3 25 | $262.6M | $133.6M | ||
| Q2 25 | $217.8M | $102.1M | ||
| Q1 25 | $149.8M | $70.3M | ||
| Q4 24 | $144.9M | $41.8M | ||
| Q3 24 | $145.0M | $176.7M | ||
| Q2 24 | $240.1M | $161.6M | ||
| Q1 24 | $228.6M | $152.8M |
| Q4 25 | $540.7M | $101.1M | ||
| Q3 25 | $505.8M | $107.0M | ||
| Q2 25 | $436.8M | $102.8M | ||
| Q1 25 | $418.6M | $82.9M | ||
| Q4 24 | $403.7M | $69.3M | ||
| Q3 24 | $405.9M | $52.7M | ||
| Q2 24 | $455.8M | $52.0M | ||
| Q1 24 | $452.0M | $62.4M |
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.4B | $1.3B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.3B | $810.7M | ||
| Q2 24 | $920.8M | $802.7M | ||
| Q1 24 | $914.5M | $809.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $8.5M |
| Free Cash FlowOCF − Capex | $29.1M | $-25.4M |
| FCF MarginFCF / Revenue | 11.8% | -11.0% |
| Capex IntensityCapex / Revenue | 0.5% | 14.7% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $65.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $8.5M | ||
| Q3 25 | $44.1M | $46.8M | ||
| Q2 25 | $75.8M | $36.7M | ||
| Q1 25 | $35.0M | $32.5M | ||
| Q4 24 | $15.9M | $-38.3M | ||
| Q3 24 | $12.5M | $25.1M | ||
| Q2 24 | $17.4M | $24.9M | ||
| Q1 24 | $18.3M | $29.7M |
| Q4 25 | $29.1M | $-25.4M | ||
| Q3 25 | $38.0M | $27.3M | ||
| Q2 25 | $71.8M | $33.5M | ||
| Q1 25 | $32.5M | $29.7M | ||
| Q4 24 | $13.5M | $-42.6M | ||
| Q3 24 | $7.7M | $20.7M | ||
| Q2 24 | $13.0M | $21.6M | ||
| Q1 24 | $13.7M | $28.2M |
| Q4 25 | 11.8% | -11.0% | ||
| Q3 25 | 16.7% | 12.2% | ||
| Q2 25 | 34.0% | 14.8% | ||
| Q1 25 | 16.5% | 12.9% | ||
| Q4 24 | 7.1% | -30.9% | ||
| Q3 24 | 5.2% | 20.6% | ||
| Q2 24 | 9.4% | 21.1% | ||
| Q1 24 | 10.0% | 27.0% |
| Q4 25 | 0.5% | 14.7% | ||
| Q3 25 | 2.7% | 8.7% | ||
| Q2 25 | 1.9% | 1.4% | ||
| Q1 25 | 1.3% | 1.2% | ||
| Q4 24 | 1.3% | 3.1% | ||
| Q3 24 | 3.2% | 4.4% | ||
| Q2 24 | 3.2% | 3.3% | ||
| Q1 24 | 3.3% | 1.4% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 2.87× | ||
| Q1 25 | 2.23× | 2.70× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.36× | ||
| Q2 24 | — | 29.74× | ||
| Q1 24 | 1.00× | 0.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
GOGO
| Services | $191.9M | 83% |
| Products | $38.7M | 17% |
| Fcc Reimbursement Program | $2.0M | 1% |
